Early trial halted for experimental fatty liver drug
NCT ID NCT04004325
Summary
This early-stage study aimed to test the safety and initial effectiveness of an investigational drug called FT-4101 for people with NASH, a serious type of fatty liver disease, who are also overweight or obese. It involved a small group of 14 participants and was designed to see if the drug could reduce the amount of fat in the liver. The study was terminated early, and its results are not publicly available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Catalina Research Institute
Montclair, California, 91763, United States
-
ProSciento, Inc.
Chula Vista, California, 91911, United States
Conditions
Explore the condition pages connected to this study.